Savant Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Savant Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-57,565	Closed	-$187K	–	1428
2024 Q3	$187K	Sell	57,565 -38,313	-40%	-$86.1K	﹤0.01%	1289
2024 Q2	$182K	Buy	+95,878	New	+$186K	﹤0.01%	1147

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Savant Capital's AMLX Position: Q4 2024 in Review

Savant Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 57,565 shares — an estimated $187K sold.

Savant Capital first reported a position in AMLX in Q2 2024 and held it in 2 quarters. The position peaked at $187K in Q3 2024. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

Savant Capital reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Savant Capital sold 57,565 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $187K.
Savant Capital first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 2 quarters.
Savant Capital's Amylyx Pharmaceuticals position peaked at $187K in Q3 2024.
122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on Savant Capital's 13F filing for Q4 2024, filed 29 Jan 2025.